← All trials
NCT02447432
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2015
- Primary completion
- Jan 23, 2016
- Completion date
- May 22, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
- diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
- pneumococcal 7-valent conjugate vaccine
- pneumococcal 7-valent conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.